{
    "clinical_study": {
        "@rank": "31765", 
        "acronym": "ADAM", 
        "arm_group": {
            "arm_group_label": "Biomarker study", 
            "arm_group_type": "Other", 
            "description": "Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF"
        }, 
        "brief_summary": {
            "textblock": "The purpose of our study is to investigate CSF and blood biomarkers among the subjects with\n      mild cognitive impairment (MCI) and Alzheimer's disease (AD) as well as normal controls."
        }, 
        "brief_title": "Biomarker Study to Diagnose Alzheimer's Disease", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Alzheimer Disease", 
            "Mild Cognitive Impairment"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alzheimer Disease", 
                "Cognition Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "Alzheimer's disease is the most prevalent cause of dementia. A biomarker is a variable that\n      are measured in vivo and indicate specific features of disease related molecular mechanisms\n      and pathologic changes, including amyloid processing and aggregation, tau\n      hyperphosphorylation, accumulation of neurofibrillary tangles, synaptic dysfunction,\n      neurodegeneration, and loss of brain tissue.\n\n      We examine serum oligomeric beta-amyloid 42 and CSF monomeric beta-amyloid 42, total tau and\n      phosphorylated tau, as well as PiB-PET, FDG-PET and brain MRI in 90 participants (30 normal\n      controls, 30 patients with mild cognitive impairment, 30 patients with Alzheimer's disease)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed and dated written informed consent obtained from the subject or the subject's\n             legally acceptable representative ( if applicable) in accordance with the local\n             regularities.\n\n          2. Both male and female, aged > 50 and <90, if women, must have no childbearing\n             potential\n\n          3. Controls did not have subjective memory complaints or any of 28 diseases and did not\n             have a history suggestive of a decrease in cognitive function (stroke or transient\n             ischemic attack, seizures, Parkinson's disease, multiple sclerosis, cerebral palsy,\n             Huntington's disease, encephalitis, meningitis, brain surgery, vascular surgery of\n             the brain, diabetes requiring insulin control, improperly managed hypertension,\n             cancer diagnosed within the past 3 years excluding skin cancer, shortness of breath\n             while sitting still, use of home oxygen, heart attack with changes in memory,\n             walking, or solving problems lasting at least 24 hours afterwards, kidney dialysis,\n             liver disease, hospitalization for mental or emotional problems in the past 5 years,\n             current use of medications for mental or emotional problems, alcohol consumption\n             greater than 3 drinks each day, drug abuse in the past 5 years, treatment for alcohol\n             abuse in the past 5 years, unconsciousness for more than one hour other than during\n             surgery, overnight hospitalization due to head injury, illness causing a permanent\n             decrease in memory or other mental functions, trouble with vision that prevents\n             reading ordinary print even with glasses, or difficulty understanding conversations\n             because of hearing even with a hearing aid)\n\n          4. The controls also had scores that were at least one standard deviation above the mean\n             scores of the respective age- and education-matched population on the K-MMSE and an\n             average score of 0.42 or less on the Korean Instrumental Activities of Daily Living\n             (K-IADL)\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "90 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01874418", 
            "org_study_id": "ADAM"
        }, 
        "intervention": {
            "arm_group_label": "Biomarker study", 
            "description": "Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF", 
            "intervention_name": "Biomarker", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 6, 2013", 
        "location": {
            "contact": {
                "email": "kumimesy@gmail.com", 
                "last_name": "Young Ho Park, MD", 
                "phone": "82-10-6287-8084"
            }, 
            "facility": {
                "address": {
                    "city": "Seongnam-si", 
                    "country": "Korea, Republic of", 
                    "state": "Gyeonggi-do", 
                    "zip": "463-707"
                }, 
                "name": "Seoul National University College of Medicine, Seoul National University Bundang Hospital"
            }, 
            "investigator": {
                "last_name": "Youg Ho Park, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Study for Usefulness and Standardization of CSF and Blood Biomarkers in Alzheimer's Disease", 
        "other_outcome": [
            {
                "description": "To compare the uptake of PiB PET among normal controls, MCI and AD", 
                "measure": "PiB PET", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "To compare the pattern of hypometabolism with FDG-PET among normal controls, MCI and AD", 
                "measure": "FDG-PET", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "To compare the volumetry and surface morphometry of brain T1-weighted MRI among normal controls, MCI and AD", 
                "measure": "Brain MRI", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }
        ], 
        "overall_contact": {
            "email": "kumimesy@gmail.com", 
            "last_name": "Young Ho Park, MD", 
            "phone": "82-10-6287-8084"
        }, 
        "overall_contact_backup": {
            "email": "neuroksy@snu.ac.kr", 
            "last_name": "SangYun Kim, MD, PhD", 
            "phone": "82-31-787-7462"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare oligomeric beta-amyloid 42 in serum among normal controls, MCI and AD", 
            "measure": "Oligomeric beta-amyloid 42 in serum", 
            "safety_issue": "No", 
            "time_frame": "baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01874418"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "SangYun Kim", 
            "investigator_title": "Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare total tau concentration in CSF among normal controls, MCI and AD", 
                "measure": "Total tau concentration in CSF", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "To compare phosphorylated tau concentration in CSF among normal controls, MCI and AD", 
                "measure": "Phosphorylated tau concentration in CSF", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "To compare monomeric beta-amyloid 42 in CSF among normal controls, MCI and AD", 
                "measure": "Monomeric beta-amyloid 42 in CSF", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}